Dynavax Technolo Stock Price, News & Analysis

Dynavax Technologies (Nasdaq: DVAX), a commercial-stage biopharmaceutical company focused on innovative vaccine development, announced its upcoming presentation at William Blair's 45th Annual Growth Stock Conference on June 3rd at 2:40 p.m. CT. The presentation will be accessible via webcast through the company's investor relations website.

Dynavax currently markets two commercial products: HEPLISAV-B® vaccine, approved in the U.S., EU, and UK for hepatitis B virus prevention in adults 18 and older, and CpG 1018® adjuvant, which is used in HEPLISAV-B and various COVID-19 vaccines.

Deep Track Capital, holding a 14.82% stake in Dynavax Technologies (NASDAQ: DVAX), has issued a critical letter to shareholders ahead of the 2025 Annual Meeting. The letter highlights significant concerns about DVAX's performance, including a 26% year-to-date share price decline and an 11% drop following Q1 2025 earnings.

The investment firm criticizes Dynavax's management for being complacent about Heplisav's slowing market share growth, which reached only 43% in Q1 2025, falling short of management's 60% target by 2030. Deep Track is nominating four directors to the board, aiming to bring shareholder-aligned perspective, vaccine commercialization expertise, and capital allocation experience.

The letter emphasizes that Dynavax failed to meet its 2024 targets of 47% market share and $275 million in U.S. sales for Heplisav, while questioning recent strategic decisions, including the new pandemic flu vaccine program.

Dynavax Technologies (DVAX) issued a correction to its stockholder letter regarding value generation metrics, revising from "$1 billion and 104% return" to "over $900 million and 62% return" versus the S&P Biotechnology Index. The company is currently engaged in a proxy battle with Deep Track Capital, defending its strategic direction and urging shareholders to vote for its four director nominees at the June 11, 2025 Annual Meeting.

The company reported strong Q1 2025 results with total revenue of $68.2 million (34% YoY increase), including HEPLISAV-B® revenue of $65 million (36% YoY increase). HEPLISAV-B® achieved ~43% U.S. market share. Dynavax has completed 85% of its $200 million share repurchase program and announced new pipeline programs including Pandemic Influenza and Lyme Disease vaccines.

Deep Track Capital, holding approximately 14.53% of Dynavax Technologies (NASDAQ: DVAX) shares, has released an investor presentation titled "The Path to Creating and Preserving Value at Dynavax." As one of DVAX's largest shareholders, Deep Track aims to enhance boardroom objectivity and implement shareholder-aligned capital allocation decisions through their four board nominees. The presentation, available at www.RefocusDVAX.com, outlines their strategy for maximizing shareholder value.